Day One

• Reflecting on the evolution of the TPD field, from early degrader design principles to today’s landscape of molecular glues and emerging proximity modalities
• Showcasing latest advances from the Ciulli Lab in mechanistic understanding and chemical biology of degraders, including unpublished data on previously undruggable targets and ternary complex formation
• Highlighting collaborative academic and industry consortia tackling grand challenges in paediatric cancers and neurodegenerative diseases
• Exploring the translational frontier, from spin-out innovation and pharma partnerships to future directions that will define the next generation of proximity-based therapeutics

New Data

• Defining PK/PD and mechanistic drivers of a first-in-class molecular glue degrader to inform dose selection, therapeutic window expectations and early safety strategy
• Integrating modelling, biomarker planning and preclinical pharmacology to justify indication prioritisation and guide a robust first-in-human study design
• Building a scalable development framework that enables pipeline expansion into non-oncology indications while maintaining selectivity, safety and chronic-use suitability

• Delivering first-in-human clinical findings from the world’s inaugural autophagy-targeting degrader for neurodegenerative disease
• Demonstrating safety, pharmacokinetics, and exposure outcomes from single- and multiple-ascending dose studies to validate clinical feasibility
• Advancing formulation and translational development of ATB2005A in canine dementia models to strengthen cross-species proof-of-concept and accelerate therapeutic advancement

Clinical Update

This networking session is your opportunity to get face-to-face with many of the brightest minds working in TPD and induced proximity to establish meaningful connections to pursue for the rest of the conference

• Elucidating the mechanistic drivers of ternary complex formation to improve predictability in molecular glue discovery
• Designing assays that detect and stabilise protein–protein interactions under the right biophysical conditions to enhance screening accuracy
• Applying mechanistic insights to build models that guide hit identification and inform future induced proximity modalities beyond molecular glues

New Data

• Building quantitative models that describe ternary complex behaviour and support mechanistic interpretation of molecular glue function in early discovery
• Optimising biochemical assay design and conditions to maximise the likelihood of identifying novel molecular glue candidates during screening.
• Integrating modelling outputs and in vitro characterisation workflows into optimisation campaigns to derive the key thermodynamic parameters of the molecular glue candidates

• New approaches to detect ubiquitination
• Enabling characterization of intrinsic and cell-specific degradation mechanisms
• Profiling neosubstrate degradation across cell types to de-risk candidates

• Applying phenotypic and functional genomics screens to uncover novel E3 ligases with translational relevance
• Establishing mechanistic and in vivo validation to demonstrate degrader efficacy and tissue selectivity
• Exploring the potential for broad target applicability and therapeutic versatility of emerging ligase systems

• Integrating structural biology, bioinformatics and chemoinformatics to rationally design Targeted Glues™ that achieve selective degradation across diverse targets
• Demonstrating mechanistic insights and preclinical progress of SMART T degraders employing distinct E3 ligases to validate platform versatility
• Applying structure-guided principles to accelerate translation of novel glue–ligase combinations from discovery to clinical readiness

• Discussing the requirements of a successful molecular glue design platform
• Blending the speed and scalability of machine learning with the accuracy of physics based methods for optimal protein-protein matching and ternary complex structure prediction
• Computational design and experimental validation of optimised molecular glue degraders and activators

• High-throughput interactomics maps the gluable target space.
• Deep proteomic library screening identifies molecular glue hits at scale.
• Ultra-sensitive global ubiquitinomics validates degrader mechanism of action.
• Proteome-wide profiling accelerates hit progression and de-risks lead optimization.

Contribute to the conversation and showcase your groundbreaking research in TPD and induced proximity drug discovery and development. To present a poster, register your place and submit an abstract highlighting your latest discovery

• Assessing the strengths, limitations and translational value of phenotypic screening for discovering novel proximity therapeutics
• Comparing biology-first and chemistry-first approaches, and how each guides hit identification, mechanistic validation and modality selection
• Exploring how biology-first strategies and complex disease-relevant assays can unlock non-degrader modalities such as stabilisers, modulators and activators
• Integrating AI-driven modelling and in silico cooperativity prediction with phenotypic and mechanistic workflows to accelerate molecular glue discovery

• Demonstrating how the AIMS (AI + MS) platform integrates AI modelling and structural proteomics to map protein interactions and inform degrader design
• Showcasing lead optimisation strategies to enhance efficacy, selectivity, and rational design of molecular glues and degraders
• Presenting preclinical results from Protai’s CAR-T6 degrader program as a case study of data-driven optimisation from discovery to in vivo validation

• Applying computational and AI-driven discovery workflows to design plant-specific degraders and glues with novel E3 ligases
• Translating human-targeted induced proximity principles into plant biology to expand modality reach beyond traditional therapeutics
• Exploring how agricultural molecular glues can inform next-generation discovery in human health through shared mechanistic insights

New Data

Noval Ligase